{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:44:51Z","timestamp":1788371091386,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":95,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031430046","type":"print"},{"value":"9783031430053","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/7854_2023_443","type":"book-chapter","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T10:03:05Z","timestamp":1692180185000},"page":"289-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Enhancing Fear Extinction: Pharmacological Approaches"],"prefix":"10.1007","author":[{"given":"Olga Y.","family":"Ponomareva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fenster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Ressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"issue":"8","key":"443_CR1","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","volume":"47","author":"CG Abdallah","year":"2022","unstructured":"Abdallah CG, Roache JD, Gueorguieva R et al (2022) Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 47(8):1574\u20131581. https:\/\/doi.org\/10.1038\/s41386-022-01266-9","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"443_CR2","doi-asserted-by":"publisher","first-page":"17m11634","DOI":"10.4088\/JCP.17m11634","volume":"79","author":"CS Albott","year":"2018","unstructured":"Albott CS, Lim KO, Forbes MK et al (2018) Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 79(3):17m11634. https:\/\/doi.org\/10.4088\/JCP.17m11634","journal-title":"J Clin Psychiatry"},{"key":"443_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0022-510X(02)00281-2","volume":"203-204","author":"F Amenta","year":"2002","unstructured":"Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F (2002) Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension. J Neurol Sci 203-204:147\u2013151. https:\/\/doi.org\/10.1016\/S0022-510X(02)00281-2","journal-title":"J Neurol Sci"},{"issue":"5","key":"443_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1601-183X.2012.00801.x","volume":"11","author":"R Andero","year":"2012","unstructured":"Andero R, Ressler KJ (2012) Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav 11(5):503\u2013512. https:\/\/doi.org\/10.1111\/j.1601-183X.2012.00801.x","journal-title":"Genes Brain Behav"},{"issue":"2","key":"443_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1176\/appi.ajp.2010.10030326","volume":"168","author":"R Andero","year":"2011","unstructured":"Andero R, Heldt SA, Ye K, Liu X, Armario A, Ressler KJ (2011) Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am J Psychiatry 168(2):163\u2013172. https:\/\/doi.org\/10.1176\/appi.ajp.2010.10030326","journal-title":"Am J Psychiatry"},{"issue":"1","key":"443_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","volume":"10","author":"C Anderson","year":"2011","unstructured":"Anderson C, Teo K, Gao P et al (2011) Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 10(1):43\u201353. https:\/\/doi.org\/10.1016\/S1474-4422(10)70250-7","journal-title":"Lancet Neurol"},{"issue":"3","key":"443_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.biopsych.2021.07.017","volume":"91","author":"P Antonoudiou","year":"2022","unstructured":"Antonoudiou P, Colmers PLW, Walton NL et al (2022) Allopregnanolone mediates affective switching through modulation of oscillatory states in the basolateral amygdala. Biol Psychiatry 91(3):283\u2013293. https:\/\/doi.org\/10.1016\/j.biopsych.2021.07.017","journal-title":"Biol Psychiatry"},{"key":"443_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.brainres.2007.01.037","volume":"1142","author":"I Armando","year":"2007","unstructured":"Armando I, Volpi S, Aguilera G, Saavedra JM (2007) Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 1142:92\u201399. https:\/\/doi.org\/10.1016\/j.brainres.2007.01.037","journal-title":"Brain Res"},{"issue":"7354","key":"443_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E et al (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475(7354):91\u201395. https:\/\/doi.org\/10.1038\/nature10130","journal-title":"Nature"},{"issue":"2","key":"443_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.9740\/mhc.2017.03.088","volume":"7","author":"JF Baker","year":"2017","unstructured":"Baker JF, Cates ME, Luthin DR (2017) D-cycloserine in the treatment of posttraumatic stress disorder. Ment Health Clin 7(2):88\u201394. https:\/\/doi.org\/10.9740\/mhc.2017.03.088","journal-title":"Ment Health Clin"},{"key":"443_CR11","first-page":"136","volume":"3","author":"H Baron","year":"1955","unstructured":"Baron H, Epstein IG, Mulinos MG, Nair KG (1955) Absorption, distribution, and excretion of cycloserine in man. Antibiot Annu 3:136\u2013140","journal-title":"Antibiot Annu"},{"key":"443_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.07.002","volume":"180","author":"MD Berry","year":"2017","unstructured":"Berry MD, Gainetdinov RR, Hoener MC, Shahid M (2017) Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther 180:161\u2013180. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.07.002","journal-title":"Pharmacol Ther"},{"issue":"15","key":"443_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2146\/ajhp140523","volume":"72","author":"K Betthauser","year":"2015","unstructured":"Betthauser K, Pilz J, Vollmer LE (2015) Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health-Syst Pharm 72(15):1279\u20131284. https:\/\/doi.org\/10.2146\/ajhp140523","journal-title":"Am J Health-Syst Pharm"},{"issue":"12","key":"443_CR14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G et al (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 6(12):995\u20131010. https:\/\/doi.org\/10.1016\/S2215-0366(19)30401-8","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"443_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1152\/physrev.00016.2020","volume":"101","author":"ME Bouton","year":"2021","unstructured":"Bouton ME, Maren S, McNally GP (2021) Behavioral and neurobiological mechanisms of Pavlovian and instrumental extinction learning. Physiol Rev 101(2):611\u2013681. https:\/\/doi.org\/10.1152\/physrev.00016.2020","journal-title":"Physiol Rev"},{"issue":"5","key":"443_CR16","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1016\/j.biopsych.2015.06.008","volume":"78","author":"ME Bowers","year":"2015","unstructured":"Bowers ME, Ressler KJ (2015) An overview of translationally informed treatments for posttraumatic stress disorder: animal models of Pavlovian fear conditioning to human clinical trials. Biol Psychiatry 78(5):E15\u2013E27. https:\/\/doi.org\/10.1016\/j.biopsych.2015.06.008","journal-title":"Biol Psychiatry"},{"issue":"6","key":"443_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/10253890801892040","volume":"11","author":"C Bregonzio","year":"2008","unstructured":"Bregonzio C, Seltzer A, Armando I, Pavel J, Saavedra JM (2008) Angiotensin II AT 1 receptor blockade selectively enhances brain AT 2 receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress 11(6):457\u2013466. https:\/\/doi.org\/10.1080\/10253890801892040","journal-title":"Stress"},{"key":"443_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fphar.2013.00161","volume":"4","author":"CA Browne","year":"2013","unstructured":"Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161. https:\/\/doi.org\/10.3389\/fphar.2013.00161","journal-title":"Front Pharmacol"},{"issue":"1","key":"443_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.nlm.2012.04.004","volume":"98","author":"SD Chang","year":"2012","unstructured":"Chang SD, Liang KC (2012) Roles of hippocampal GABAA and muscarinic receptors in consolidation of context memory and context\u2013shock association in contextual fear conditioning: a double dissociation study. Neurobiol Learn Mem 98(1):17\u201324. https:\/\/doi.org\/10.1016\/j.nlm.2012.04.004","journal-title":"Neurobiol Learn Mem"},{"issue":"1742","key":"443_CR20","doi-asserted-by":"publisher","first-page":"20170025","DOI":"10.1098\/rstb.2017.0025","volume":"373","author":"MG Craske","year":"2018","unstructured":"Craske MG, Hermans D, Vervliet B (2018) State-of-the-art and future directions for extinction as a translational model for fear and anxiety. Philos Trans R Soc B Biol Sci 373(1742):20170025. https:\/\/doi.org\/10.1098\/rstb.2017.0025","journal-title":"Philos Trans R Soc B Biol Sci"},{"issue":"9","key":"443_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.biopsych.2019.04.012","volume":"86","author":"MG Craske","year":"2019","unstructured":"Craske MG, Fanselow M, Treanor M, Bystritksy A (2019) Cholinergic modulation of exposure disrupts hippocampal processes and augments extinction: proof-of-concept study with social anxiety disorder. Biol Psychiatry 86(9):703\u2013711. https:\/\/doi.org\/10.1016\/j.biopsych.2019.04.012","journal-title":"Biol Psychiatry"},{"key":"443_CR22","doi-asserted-by":"publisher","first-page":"247054702098167","DOI":"10.1177\/2470547020981670","volume":"4","author":"AR Dadabayev","year":"2020","unstructured":"Dadabayev AR, Joshi SA, Reda MH et al (2020) Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial. Chronic Stress (Thousand Oaks) 4:2470547020981670. https:\/\/doi.org\/10.1177\/2470547020981670","journal-title":"Chronic Stress (Thousand Oaks)"},{"key":"443_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.brainres.2018.01.006","volume":"1682","author":"M Dadkhah","year":"2018","unstructured":"Dadkhah M, Abdullahi PR, Rashidy-Pour A, Sameni HR, Vafaei AA (2018) Infralimbic dopamine D2 receptors mediate glucocorticoid-induced facilitation of auditory fear memory extinction in rats. Brain Res 1682:84\u201392. https:\/\/doi.org\/10.1016\/j.brainres.2018.01.006","journal-title":"Brain Res"},{"issue":"3","key":"443_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ecl.2013.05.004","volume":"42","author":"NP Daskalakis","year":"2013","unstructured":"Daskalakis NP, Lehrner A, Yehuda R (2013) Endocrine aspects of post-traumatic stress disorder and implications for diagnosis and treatment. Endocrinol Metab Clin North Am 42(3):503\u2013513. https:\/\/doi.org\/10.1016\/j.ecl.2013.05.004","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"443_CR25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/npp.2013.317","volume":"39","author":"J Difede","year":"2014","unstructured":"Difede J, Cukor J, Wyka K et al (2014) D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 39(5):1052\u20131058. https:\/\/doi.org\/10.1038\/npp.2013.317","journal-title":"Neuropsychopharmacology"},{"key":"443_CR26","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1038\/ncomms7395","volume":"6","author":"I Dincheva","year":"2015","unstructured":"Dincheva I, Drysdale AT, Hartley CA et al (2015) FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat Commun 6:6395. https:\/\/doi.org\/10.1038\/ncomms7395","journal-title":"Nat Commun"},{"issue":"20","key":"443_CR27","doi-asserted-by":"publisher","first-page":"8689","DOI":"10.1523\/JNEUROSCI.4483-12.2013","volume":"33","author":"V Douchamps","year":"2013","unstructured":"Douchamps V, Jeewajee A, Blundell P, Burgess N, Lever C (2013) Evidence for encoding versus retrieval scheduling in the hippocampus by theta phase and acetylcholine. J Neurosci 33(20):8689\u20138704. https:\/\/doi.org\/10.1523\/JNEUROSCI.4483-12.2013","journal-title":"J Neurosci"},{"issue":"7","key":"443_CR28","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1523\/JNEUROSCI.5390-09.2010","volume":"30","author":"SM Dravid","year":"2010","unstructured":"Dravid SM, Burger PB, Prakash A et al (2010) Structural determinants of D-cycloserine efficacy at the NR1\/NR2C NMDA receptors. J Neurosci 30(7):2741\u20132754. https:\/\/doi.org\/10.1523\/JNEUROSCI.5390-09.2010","journal-title":"J Neurosci"},{"issue":"5","key":"443_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/s0006-3223(98)00031-6","volume":"44","author":"RS Duman","year":"1998","unstructured":"Duman RS (1998) Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 44(5):324\u2013335. https:\/\/doi.org\/10.1016\/s0006-3223(98)00031-6","journal-title":"Biol Psychiatry"},{"issue":"4","key":"443_CR30","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17470910802649470","volume":"4","author":"GJH Dumont","year":"2009","unstructured":"Dumont GJH, Sweep FCGJ, van der Steen R et al (2009) Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 4(4):359\u2013366. https:\/\/doi.org\/10.1080\/17470910802649470","journal-title":"Soc Neurosci"},{"issue":"12","key":"443_CR31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.biopsych.2017.06.024","volume":"82","author":"BW Dunlop","year":"2017","unstructured":"Dunlop BW, Binder EB, Iosifescu D et al (2017) Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder. Biol Psychiatry 82(12):866\u2013874. https:\/\/doi.org\/10.1016\/j.biopsych.2017.06.024","journal-title":"Biol Psychiatry"},{"key":"443_CR32","doi-asserted-by":"publisher","first-page":"699740","DOI":"10.3389\/fpsyt.2021.699740","volume":"12","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Odisho AS, Lewis K et al (2021) Brexanolone, a GABAA modulator, in the treatment of postpartum depression in adults: a comprehensive review. Front Psych 12:699740. https:\/\/doi.org\/10.3389\/fpsyt.2021.699740","journal-title":"Front Psych"},{"issue":"3","key":"443_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/spc3.12089","volume":"8","author":"D Edmondson","year":"2014","unstructured":"Edmondson D (2014) An enduring somatic threat model of posttraumatic stress disorder due to acute life-threatening medical events: enduring somatic threat model. Soc Personal Psychol Compass 8(3):118\u2013134. https:\/\/doi.org\/10.1111\/spc3.12089","journal-title":"Soc Personal Psychol Compass"},{"issue":"1\u20133","key":"443_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s0301-0511(01)00092-8","volume":"57","author":"U Ehlert","year":"2001","unstructured":"Ehlert U, Gaab J, Heinrichs M (2001) Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol Psychol 57(1\u20133):141\u2013152. https:\/\/doi.org\/10.1016\/s0301-0511(01)00092-8","journal-title":"Biol Psychol"},{"issue":"6","key":"443_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","volume":"71","author":"A Feder","year":"2014","unstructured":"Feder A, Parides MK, Murrough JW et al (2014) Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71(6):681\u2013688. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.62","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"443_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","volume":"178","author":"A Feder","year":"2021","unstructured":"Feder A, Costi S, Rutter SB et al (2021) A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193\u2013202. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20050596","journal-title":"Am J Psychiatry"},{"key":"443_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.psyneuen.2015.11.001","volume":"64","author":"JA Golier","year":"2016","unstructured":"Golier JA, Caramanica K, Michaelides AC et al (2016) A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in gulf war veterans with chronic multisymptom illness. Psychoneuroendocrinology 64:22\u201330. https:\/\/doi.org\/10.1016\/j.psyneuen.2015.11.001","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"443_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00213-002-1131-1","volume":"162","author":"DS Harris","year":"2002","unstructured":"Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 162(4):396\u2013405. https:\/\/doi.org\/10.1007\/s00213-002-1131-1","journal-title":"Psychopharmacology (Berl)"},{"key":"443_CR39","doi-asserted-by":"publisher","first-page":"e749","DOI":"10.1038\/tp.2016.26","volume":"6","author":"ND Hartley","year":"2016","unstructured":"Hartley ND, Gunduz-Cinar O, Halladay L, Bukalo O, Holmes A, Patel S (2016) 2-arachidonoylglycerol signaling impairs short-term fear extinction. Transl Psychiatry 6:e749. https:\/\/doi.org\/10.1038\/tp.2016.26","journal-title":"Transl Psychiatry"},{"issue":"1","key":"443_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/npp.2017.162","volume":"43","author":"MN Hill","year":"2018","unstructured":"Hill MN, Campolongo P, Yehuda R, Patel S (2018) Integrating endocannabinoid signaling and cannabinoids into the biology and treatment of posttraumatic stress disorder. Neuropsychopharmacology 43(1):80\u2013102. https:\/\/doi.org\/10.1038\/npp.2017.162","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"443_CR41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/bja\/77.4.441","volume":"77","author":"K Hirota","year":"1996","unstructured":"Hirota K, Lambert DG (1996) Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 77(4):441\u2013444. https:\/\/doi.org\/10.1093\/bja\/77.4.441","journal-title":"Br J Anaesth"},{"issue":"7","key":"443_CR42","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/gbb.12235","volume":"14","author":"RC Hurt","year":"2015","unstructured":"Hurt RC, Garrett JC, Keifer OP et al (2015) Angiotensin type 1a receptors on corticotropin-releasing factor neurons contribute to the expression of conditioned fear. Genes Brain Behav 14(7):526\u2013533. https:\/\/doi.org\/10.1111\/gbb.12235","journal-title":"Genes Brain Behav"},{"key":"443_CR43","doi-asserted-by":"publisher","unstructured":"Inslicht SS, Niles AN, Metzler TJ et al (2021) Randomized controlled experimental study of hydrocortisone and D-cycloserine effects on fear extinction in PTSD. Neuropsychopharmacology 19. https:\/\/doi.org\/10.1038\/s41386-021-01222-z","DOI":"10.1038\/s41386-021-01222-z"},{"issue":"6","key":"443_CR44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4088\/JCP.11m07316","volume":"73","author":"NM Khoury","year":"2012","unstructured":"Khoury NM, Marvar PJ, Gillespie CF et al (2012) The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J Clin Psychiatry 73(6):849\u2013855. https:\/\/doi.org\/10.4088\/JCP.11m07316","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"443_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199\u2013214. https:\/\/doi.org\/10.1001\/archpsyc.1994.03950030035004","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"443_CR46","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1037\/0735-7044.117.2.341","volume":"117","author":"L Ledgerwood","year":"2003","unstructured":"Ledgerwood L, Richardson R, Cranney J (2003) Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 117(2):341\u2013349. https:\/\/doi.org\/10.1037\/0735-7044.117.2.341","journal-title":"Behav Neurosci"},{"issue":"9","key":"443_CR47","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/da.22511","volume":"33","author":"DJ Lee","year":"2016","unstructured":"Lee DJ, Schnitzlein CW, Wolf JP, Vythilingam M, Rasmusson AM, Hoge CW (2016) Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety 33(9):792\u2013806. https:\/\/doi.org\/10.1002\/da.22511","journal-title":"Depress Anxiety"},{"issue":"3","key":"443_CR48","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1101\/lm.217006","volume":"13","author":"HC Lin","year":"2006","unstructured":"Lin HC, Mao SC, Gean PW (2006) Effects of intra-amygdala infusion of CB1 receptor agonists on the reconsolidation of fear-potentiated startle. Learn Mem 13(3):316\u2013321. https:\/\/doi.org\/10.1101\/lm.217006","journal-title":"Learn Mem"},{"key":"443_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.janxdis.2018.10.006","volume":"61","author":"JL Maples-Keller","year":"2019","unstructured":"Maples-Keller JL, Jovanovic T, Dunlop BW et al (2019) When translational neuroscience fails in the clinic: dexamethasone prior to virtual reality exposure therapy increases drop-out rates. J Anxiety Disord 61:89\u201397. https:\/\/doi.org\/10.1016\/j.janxdis.2018.10.006","journal-title":"J Anxiety Disord"},{"key":"443_CR50","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.brainres.2014.10.010","volume":"1621","author":"S Maren","year":"2015","unstructured":"Maren S (2015) Out with the old and in with the new: synaptic mechanisms of extinction in the amygdala. Brain Res 1621:231\u2013238. https:\/\/doi.org\/10.1016\/j.brainres.2014.10.010","journal-title":"Brain Res"},{"issue":"6897","key":"443_CR51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature00839","volume":"418","author":"G Marsicano","year":"2002","unstructured":"Marsicano G, Wotjak CT, Azad SC et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418(6897):530\u2013534. https:\/\/doi.org\/10.1038\/nature00839","journal-title":"Nature"},{"issue":"11","key":"443_CR52","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.biopsych.2013.08.024","volume":"75","author":"PJ Marvar","year":"2014","unstructured":"Marvar PJ, Goodman J, Fuchs S, Choi DC, Banerjee S, Ressler KJ (2014) Angiotensin type 1 receptor inhibition enhances the extinction of fear memory. Biol Psychiatry 75(11):864\u2013872. https:\/\/doi.org\/10.1016\/j.biopsych.2013.08.024","journal-title":"Biol Psychiatry"},{"issue":"1","key":"443_CR53","first-page":"136","volume":"290","author":"M Mas","year":"1999","unstructured":"Mas M, Farr\u00e9 M, de la Torre R et al (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290(1):136\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"443_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00005053-198603000-00003","volume":"174","author":"JW Mason","year":"1986","unstructured":"Mason JW, Giller EL, Kosten TR, Ostroff RB, Podd L (1986) Urinary free-cortisol levels in posttraumatic stress disorder patients. J Nerv Ment Dis 174(3):145\u2013149. https:\/\/doi.org\/10.1097\/00005053-198603000-00003","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"443_CR55","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","volume":"74","author":"D Mataix-Cols","year":"2017","unstructured":"Mataix-Cols D, Fern\u00e1ndez de la Cruz L, Monzani B et al (2017) D-cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a systematic review and meta-analysis of individual participant data. JAMA Psychiatry 74(5):501\u2013510. https:\/\/doi.org\/10.1001\/jamapsychiatry.2016.3955","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"443_CR56","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2019.07.034","volume":"87","author":"LM Mayo","year":"2020","unstructured":"Mayo LM, Asratian A, Lind\u00e9 J et al (2020a) Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry 87(6):538\u2013547. https:\/\/doi.org\/10.1016\/j.biopsych.2019.07.034","journal-title":"Biol Psychiatry"},{"issue":"5","key":"443_CR57","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41380-018-0215-1","volume":"25","author":"LM Mayo","year":"2020","unstructured":"Mayo LM, Asratian A, Lind\u00e9 J et al (2020b) Protective effects of elevated anandamide on stress and fear-related behaviors: translational evidence from humans and mice. Mol Psychiatry 25(5):993\u20131005. https:\/\/doi.org\/10.1038\/s41380-018-0215-1","journal-title":"Mol Psychiatry"},{"issue":"3","key":"443_CR58","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.biopsych.2021.07.019","volume":"91","author":"LM Mayo","year":"2022","unstructured":"Mayo LM, Rabinak CA, Hill MN, Heilig M (2022) Targeting the endocannabinoid system in the treatment of posttraumatic stress disorder: a promising case of preclinical-clinical translation? Biol Psychiatry 91(3):262\u2013272. https:\/\/doi.org\/10.1016\/j.biopsych.2021.07.019","journal-title":"Biol Psychiatry"},{"issue":"2 Suppl","key":"443_CR59","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1097\/TA.0b013e318160ba1d","volume":"64","author":"LL McGhee","year":"2008","unstructured":"McGhee LL, Maani CV, Garza TH, Gaylord KM, Black IH (2008) The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma 64(2 Suppl):S195\u2013S198.; Discussion S197\u2013198. https:\/\/doi.org\/10.1097\/TA.0b013e318160ba1d","journal-title":"J Trauma"},{"key":"443_CR60","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.psyneuen.2017.05.023","volume":"83","author":"V Michopoulos","year":"2017","unstructured":"Michopoulos V, Norrholm SD, Stevens JS et al (2017) Dexamethasone facilitates fear extinction and safety discrimination in PTSD: a placebo-controlled, double-blind study. Psychoneuroendocrinology 83:65\u201371. https:\/\/doi.org\/10.1016\/j.psyneuen.2017.05.023","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"443_CR61","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A et al (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27(6):1025\u20131033. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"issue":"4","key":"443_CR62","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of {+\/\u2212}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol Oxf Engl 25(4):439\u2013452. https:\/\/doi.org\/10.1177\/0269881110378371","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"1","key":"443_CR63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0269881112456611","volume":"27","author":"MC Mithoefer","year":"2013","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT et al (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol Oxf Engl 27(1):28\u201339. https:\/\/doi.org\/10.1177\/0269881112456611","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"443_CR64","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.nbd.2015.06.012","volume":"82","author":"A Navarria","year":"2015","unstructured":"Navarria A, Wohleb ES, Voleti B et al (2015) Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis 82:254\u2013261. https:\/\/doi.org\/10.1016\/j.nbd.2015.06.012","journal-title":"Neurobiol Dis"},{"issue":"10","key":"443_CR65","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/hipo.22753","volume":"27","author":"EL Newman","year":"2017","unstructured":"Newman EL, Venditto SJC, Climer JR, Petter EA, Gillet SN, Levy S (2017) Precise spike timing dynamics of hippocampal place cell activity sensitive to cholinergic disruption. Hippocampus 27(10):1069\u20131082. https:\/\/doi.org\/10.1002\/hipo.22753","journal-title":"Hippocampus"},{"issue":"7","key":"443_CR66","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.pnpbp.2010.06.025","volume":"34","author":"EM Ninomiya","year":"2010","unstructured":"Ninomiya EM, Martynhak BJ, Zanoveli JM, Correia D, da Cunha C, Andreatini R (2010) Spironolactone and low-dose dexamethasone enhance extinction of contextual fear conditioning. Prog Neuropsychopharmacol Biol Psychiatry 34(7):1229\u20131235. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.06.025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"443_CR67","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41380-019-0639-2","volume":"25","author":"M Notaras","year":"2020","unstructured":"Notaras M, van den Buuse M (2020) Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders. Mol Psychiatry 25(10):2251\u20132274. https:\/\/doi.org\/10.1038\/s41380-019-0639-2","journal-title":"Mol Psychiatry"},{"issue":"4","key":"443_CR68","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/00000542-199704000-00021","volume":"86","author":"BA Orser","year":"1997","unstructured":"Orser BA, Pennefather PS, MacDonald JF (1997) Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 86(4):903\u2013917. https:\/\/doi.org\/10.1097\/00000542-199704000-00021","journal-title":"Anesthesiology"},{"issue":"4","key":"443_CR69","first-page":"273","volume":"1","author":"SJ Peroutka","year":"1988","unstructured":"Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1(4):273\u2013277","journal-title":"Neuropsychopharmacology"},{"issue":"14","key":"443_CR70","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1073\/pnas.0801853105","volume":"105","author":"F Pibiri","year":"2008","unstructured":"Pibiri F, Nelson M, Guidotti A, Costa E, Pinna G (2008) Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: a model relevant for posttraumatic stress disorder. Proc Natl Acad Sci 105(14):5567\u20135572. https:\/\/doi.org\/10.1073\/pnas.0801853105","journal-title":"Proc Natl Acad Sci"},{"key":"443_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.psyneuen.2018.04.024","volume":"93","author":"SL Pineles","year":"2018","unstructured":"Pineles SL, Nillni YI, Pinna G et al (2018) PTSD in women is associated with a block in conversion of progesterone to the GABAergic neurosteroids allopregnanolone and pregnanolone measured in plasma. Psychoneuroendocrinology 93:133\u2013141. https:\/\/doi.org\/10.1016\/j.psyneuen.2018.04.024","journal-title":"Psychoneuroendocrinology"},{"key":"443_CR72","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fncel.2014.00256","volume":"8","author":"G Pinna","year":"2014","unstructured":"Pinna G, Rasmusson AM (2014) Ganaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorder. Front Cell Neurosci 8:256. https:\/\/doi.org\/10.3389\/fncel.2014.00256","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"443_CR73","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","volume":"61","author":"KJ Ressler","year":"2004","unstructured":"Ressler KJ, Rothbaum BO, Tannenbaum L et al (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61(11):1136\u20131144. https:\/\/doi.org\/10.1001\/archpsyc.61.11.1136","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"443_CR74","doi-asserted-by":"publisher","first-page":"e93519","DOI":"10.1371\/journal.pone.0093519","volume":"9","author":"H Rodrigues","year":"2014","unstructured":"Rodrigues H, Figueira I, Lopes A et al (2014) Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PloS One 9(7):e93519. https:\/\/doi.org\/10.1371\/journal.pone.0093519","journal-title":"PloS One"},{"key":"443_CR75","doi-asserted-by":"publisher","first-page":"102149","DOI":"10.1016\/j.janxdis.2019.102149","volume":"68","author":"D Rosenfield","year":"2019","unstructured":"Rosenfield D, Smits JAJ, Hofmann SG et al (2019) Changes in dosing and dose timing of D-cycloserine explain its apparent declining efficacy for augmenting exposure therapy for anxiety-related disorders: an individual participant-data meta-analysis. J Anxiety Disord 68:102149. https:\/\/doi.org\/10.1016\/j.janxdis.2019.102149","journal-title":"J Anxiety Disord"},{"issue":"2","key":"443_CR76","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/10253890701350735","volume":"10","author":"JM Saavedra","year":"2007","unstructured":"Saavedra JM, Benicky J (2007) Brain and peripheral angiotensin II play a major role in stress. Stress Amst Neth 10(2):185\u2013193. https:\/\/doi.org\/10.1080\/10253890701350735","journal-title":"Stress Amst Neth"},{"issue":"4","key":"443_CR77","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s41386-020-00923-1","volume":"46","author":"AV Seligowski","year":"2021","unstructured":"Seligowski AV, Duffy LA, Merker JB et al (2021) The renin-angiotensin system in PTSD: a replication and extension. Neuropsychopharmacology 46(4):750\u2013755. https:\/\/doi.org\/10.1038\/s41386-020-00923-1","journal-title":"Neuropsychopharmacology"},{"key":"443_CR78","doi-asserted-by":"publisher","first-page":"108167","DOI":"10.1016\/j.biopsycho.2021.108167","volume":"165","author":"A Sewart","year":"2021","unstructured":"Sewart A, McGlade A, Treanor M, Fanselow M, Craske M (2021) Pre-treatment hippocampal functioning impacts context renewal for cholinergic modulated exposure therapy. Biol Psychol 165:108167. https:\/\/doi.org\/10.1016\/j.biopsycho.2021.108167","journal-title":"Biol Psychol"},{"key":"443_CR79","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jad.2020.08.058","volume":"277","author":"PR Shiroma","year":"2020","unstructured":"Shiroma PR, Thuras P, Wels J et al (2020) Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 277:470\u2013477. https:\/\/doi.org\/10.1016\/j.jad.2020.08.058","journal-title":"J Affect Disord"},{"key":"443_CR80","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2014.12.004","volume":"149","author":"N Singewald","year":"2015","unstructured":"Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ (2015) Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacol Ther 149:150\u2013190. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.12.004","journal-title":"Pharmacol Ther"},{"issue":"7","key":"443_CR81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.biopsych.2021.05.012","volume":"90","author":"MB Stein","year":"2021","unstructured":"Stein MB, Jain S, Simon NM et al (2021) Randomized, placebo-controlled trial of the angiotensin receptor antagonist losartan for posttraumatic stress disorder. Biol Psychiatry 90(7):473\u2013481. https:\/\/doi.org\/10.1016\/j.biopsych.2021.05.012","journal-title":"Biol Psychiatry"},{"key":"443_CR82","doi-asserted-by":"publisher","first-page":"822709","DOI":"10.3389\/fnins.2022.822709","volume":"16","author":"AA Stylianakis","year":"2022","unstructured":"Stylianakis AA, Baker KD, Richardson R (2022) Pharmacological enhancement of extinction retention in non-stressed adolescent rats but not those exposed to chronic corticosterone. Front Neurosci 16:822709. https:\/\/doi.org\/10.3389\/fnins.2022.822709","journal-title":"Front Neurosci"},{"issue":"2","key":"443_CR83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neuroscience.2007.02.032","volume":"146","author":"MR Thompson","year":"2007","unstructured":"Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (\u201cecstasy\u201d). Neuroscience 146(2):509\u2013514. https:\/\/doi.org\/10.1016\/j.neuroscience.2007.02.032","journal-title":"Neuroscience"},{"issue":"4","key":"443_CR84","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","volume":"189","author":"CD Verrico","year":"2007","unstructured":"Verrico CD, Miller GM, Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189(4):489\u2013503. https:\/\/doi.org\/10.1007\/s00213-005-0174-5","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"443_CR85","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","volume":"73","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Swanson JM, Evins AE et al (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73(3):292\u2013297. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.3278","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"443_CR86","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0893-133X(98)00013-X","volume":"19","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (\u201cecstasy\u201d) in MDMA-na\u00efve healthy volunteers. Neuropsychopharmacology 19(4):241\u2013251. https:\/\/doi.org\/10.1016\/S0893-133X(98)00013-X","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"443_CR87","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","volume":"22","author":"DL Walker","year":"2002","unstructured":"Walker DL, Ressler KJ, Lu KT, Davis M (2002) Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22(6):2343\u20132351","journal-title":"J Neurosci"},{"issue":"3","key":"443_CR88","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0269881106061514","volume":"20","author":"K Wolff","year":"2006","unstructured":"Wolff K, Tsapakis EM, Winstock AR et al (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol Oxf Engl 20(3):400\u2013410. https:\/\/doi.org\/10.1177\/0269881106061514","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"1\u20132","key":"443_CR89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.psychres.2014.09.005","volume":"225","author":"NE Wood","year":"2015","unstructured":"Wood NE, Rosasco ML, Suris AM et al (2015) Pharmacological blockade of memory reconsolidation in posttraumatic stress disorder: three negative psychophysiological studies. Psychiatry Res 225(1\u20132):31\u201339. https:\/\/doi.org\/10.1016\/j.psychres.2014.09.005","journal-title":"Psychiatry Res"},{"issue":"5","key":"443_CR90","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/sj.npp.1300899","volume":"31","author":"YL Yang","year":"2006","unstructured":"Yang YL, Chao PK, Lu KT (2006) Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacology 31(5):912\u2013924. https:\/\/doi.org\/10.1038\/sj.npp.1300899","journal-title":"Neuropsychopharmacology"},{"key":"443_CR91","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.psyneuen.2014.08.004","volume":"51","author":"R Yehuda","year":"2015","unstructured":"Yehuda R, Bierer LM, Pratchett LC et al (2015) Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: randomized trial showing improved treatment retention and outcome. Psychoneuroendocrinology 51:589\u2013597. https:\/\/doi.org\/10.1016\/j.psyneuen.2014.08.004","journal-title":"Psychoneuroendocrinology"},{"key":"443_CR92","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1038\/tp.2015.138","volume":"5","author":"MB Young","year":"2015","unstructured":"Young MB, Andero R, Ressler KJ, Howell LL (2015) 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry 5:e634. https:\/\/doi.org\/10.1038\/tp.2015.138","journal-title":"Transl Psychiatry"},{"issue":"3","key":"443_CR93","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","volume":"32","author":"P Zanos","year":"2018","unstructured":"Zanos P, Thompson SM, Duman RS, Zarate CA, Gould TD (2018) Convergent mechanisms underlying rapid antidepressant action. CNS Drugs 32(3):197\u2013227. https:\/\/doi.org\/10.1007\/s40263-018-0492-x","journal-title":"CNS Drugs"},{"issue":"4","key":"443_CR94","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopsych.2012.08.006","volume":"73","author":"M Zelikowsky","year":"2013","unstructured":"Zelikowsky M, Hast TA, Bennett RZ et al (2013) Cholinergic blockade frees fear extinction from its contextual dependency. Biol Psychiatry 73(4):345\u2013352. https:\/\/doi.org\/10.1016\/j.biopsych.2012.08.006","journal-title":"Biol Psychiatry"},{"issue":"8","key":"443_CR95","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1592\/phco.21.11.891.34524","volume":"21","author":"M Zhu","year":"2001","unstructured":"Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA (2001) Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 21(8):891\u2013897. https:\/\/doi.org\/10.1592\/phco.21.11.891.34524","journal-title":"Pharmacotherapy"}],"container-title":["Current Topics in Behavioral Neurosciences","Fear Extinction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2023_443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T20:12:17Z","timestamp":1700165537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2023_443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031430046","9783031430053"],"references-count":95,"URL":"https:\/\/doi.org\/10.1007\/7854_2023_443","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"17 August 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"This work was supported by Veterans Administration (VA) Office of Academic Affairs (OAA) Psychiatric Research\/Neurosciences Advanced Fellowship (OYP), NIH awards (P50-MH115874, R01-MH108665), and the Frazier Institute at McLean Hospital (KJR).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgments"}},{"value":"Dr. Ressler has performed scientific consultation for BioXcel, Bionomics, Acer, Takeda, and Jazz Pharma; serves on Scientific Advisory Boards for Sage and the Brain Research Foundation, and he has received sponsored research support from Takeda, BrainsWay, and Alto Neuroscience. He receives research funding from the NIH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}